The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases
Yıl: 2022 Cilt: 18 Sayı: 4 Sayfa Aralığı: 419 - 426 Metin Dili: İngilizce DOI: 10.4274/BMJ.galenos.2022.2022.2-6 İndeks Tarihi: 06-05-2023
The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases
Öz: Objective: The aim of this study was to evaluate the possible role of the chemokine CXCL12 in the pathogenesis of some diseases. It also aims to research diseases and connect with each other with bioinformatic tools. Methods: STRING/GeneMANIA/KEGG PATHWAY/GSEA/MSigDB for gene set enrichment analysis for gene protein and pathway interaction, TargetScan/miRDB for miRNAs targeting CXCL12, Blood eQTL Browser/ to target CXCL12 BIOS/QTLdb, GRASP and GWAS CXCL12 and miRNA region SNPs were used for disease associations. Results: Gene set enrichment analysis of the gene set co-expressed in the GSEA/MSigDB tool revealed the association of genes related to allergic disease, arthritis, autoimmune disease of the musculoskeletal system, osteomyelitis (FDR<5E-06). Five hundred and ninety-three miRNAs were identified. As a result of examining the disease associations of SNPs from each miRNA gene region in GWAS databases, it was determined that P<7E-40 for B lymphoblastic leukemia/lymphoma. SNPs in CXCL12 did not show any GWAS associations, but blood eQTL/ meQTL for CXCL12 showed associations with respiratory system disease, intestinal disease, combined immunodeficiency, multiple sclerosis, hepatitis (P<8E-06) and GWAS. Conclusion: It is thought that CXCL12 may play a strong role in autoimmunity, inflammation, cancer and other diseases.
Anahtar Kelime: Kemokin CXCL12’nin Bazı Hastalıkların Patogenezindeki Rolü
Öz: Amaç: Bu çalışmanın amacı kemokin CXCL12’nin bazı hastalıkların patogenezindeki olası rolünü değerlendirmektir. Ayrıca biyoinformatik araçlarla hastalıkları araştırmayı ve birbirleriyle bağlantı kurmayı amaçlamaktadır. Gereç ve Yöntem: Gen-protein ve yolak etkileşimi için STRING/GeneMANIA/KEGG PATHWAY/GeneCards gen seti zenginleştirme analizi için GSEA/MSigDB, CXCL12’yi hedefleyen miRNA’lar için TargetScan/miRDB, CXCL12’yi hedeflemek için Blood eQTL Browser/BIOS/mQTLdb, hastalık ilişkileri için GRASP ve GWAS CXCL12 ve miRNA bölgesi SNP’leri kullanıldı. Bulgular: GSEA/MSigDB aracında birlikte eksprese edilen gen setinin gen seti zenginleştirme analizi, alerjik hastalık, artrit, kas-iskelet sisteminin otoimmün hastalığı, osteomiyelit (FDR<5E-06) ile ilgili genlerin ilişkisini ortaya koydu. Beş yüz doksan üç miRNA tanımlandı. GWAS veri tabanlarında her bir miRNA gen bölgesinden SNP’lerin hastalık ilişkilerinin incelenmesi sonucunda, B-lenfoblastik lösemi/lenfoma için P<7E- 40 olduğu saptandı. CXCL12 içindeki SNP’ler herhangi bir GWAS ilişkisi göstermedi, ancak CXCL12 için kanda eQTL/meQTL olarak, solunum sistemi hastalığı, bağırsak hastalığı, kombine immün yetmezlik, multipl skleroz, hepatit (P<8E-06) ile GWAS ilişkileri gösterildi. Sonuç: CXCL12 otoimmünite, enflamasyon, kanser ve diğer hastalıklarda güçlü bir rol oynayabileceği düşünülmektedir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Gerber PA, Hippe A, Buhren BA, Müller A, Homey B. Chemokines in tumor-associated angiogenesis. Biol Chem 2009;390:1213-23.
- 2. Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 2014;9:118-28.
- 3. Tang T, Xia QJ, Qiao X, Xi M. Expression of C-X-C chemokine receptor type 7 in otorhinolaryngologic neoplasms. Singapore Med J 2016;57:157-60.
- 4. Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, et al. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Br J Haematol 2017;179:36-49.
- 5. Zhu W, Liang G, Huang Z, Doty SB, Boskey AL. Conditional inactivation of the CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to impaired osteoblast development. J Biol Chem 2011;286:26794-805.
- 6. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 2010;285:7805-17.
- 7. Janssens R, Struyf S, Proost P. The unique structural and functional features of CXCL12. Cell Mol Immunol 2018;15:299-311.
- 8. Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 2007;69:451-82.
- 9. Di Marzo L, Desantis V, Solimando AG, Ruggieri S, Annese T, Nico B, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget 2016;7:60698-711.
- 10. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 2006;25:573-87.
- 11. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin- receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 2014;15:154-68.
- 12. Aoki K, Kurashige M, Ichii M, Higaki K, Sugiyama T, Kaito T, et al. Identification of CXCL12-abundant reticular cells in human adult bone marrow. Br J Haematol 2021;193:659-68.
- 13. Brigle K, Rogers B. Pathobiology and Diagnosis of Multiple Myeloma. Semin Oncol Nurs 2017;33:225-36.
- 14. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
- 15. Sanz-Rodríguez F, Hidalgo A, Teixidó J. Chemokine stromal cell- derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001;97:346-51.
- 16. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)- dependent migration and homing in multiple myeloma. Blood 2007;109:2708-17.
- 17. Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006;91:605-12.
- 18. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-9.
- 19. Sand LG, Jochemsen AG, Beletkaia E, Schmidt T, Hogendoorn PC, Szuhai K. Novel splice variants of CXCR4 identified by transcriptome sequencing. Biochem Biophys Res Commun 2015;466:89-94.
- 20. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-8.
- 21. Takabatake Y, Sugiyama T, Kohara H, Matsusaka T, Kurihara H, Koni PA, et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J Am Soc Nephrol 2009;20:1714- 23.
- 22. Ren Z, Lantermans H, Kuil A, Kraan W, Arenzana-Seisdedos F, Kersten MJ. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. J Hematol Oncol 2021;14:11.
- 23. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-91.
- 24. Ladikou EE, Chevassut T, Pepper CJ, Pepper AG. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. Br J Haematol 2020;189:815-25.
- 25. Zhang Y, Dépond M, He L, Foudi A, Kwarteng EO, Lauret E, et al. CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. Sci Rep 2016;6:37827.
- 26. Ullah TR. The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond. J Bone Oncol 2019;17:100253.
- 27. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007;28:299-307.
- 28. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013;49:219-30.
- 29. Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over- expression and survival in cancer: a system review and meta- analysis. Oncotarget 2015;6:5022-40.
- 30. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927-31.
- 31. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein- coupled receptor. Science 1996;272:872-7.
- 32. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-7.
- 33. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000;86:131-8.
- 34. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Möpps B, et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 2005;96:784-91.
- 35. Döring Y, Pawig L, Weber C, Noels H. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol 2014;5:212.
- 36. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011;43:333-8.
- 37. Bachelerie F. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome. Dis Markers 2010;29:189-98.
- 38. Liu Q, Pan C, Lopez L, Gao J, Velez D, Anaya-O’Brien S, et al. WHIM Syndrome Caused by Waldenström’s Macroglobulinemia- Associated Mutation CXCR4 (L329fs). J Clin Immunol 2016;36:397- 405.
- 39. Lagane B, Chow KY, Balabanian K, Levoye A, Harriague J, Planchenault T, et al. CXCR4 dimerization and beta-arrestin- mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 2008;112:34-44.
- 40. Bagheri V, Khorramdelazad H, Hassanshahi G, Moghadam- Ahmadi A, Vakilian A. CXCL12 and CXCR4 in the Peripheral Blood of Patients with Parkinson’s Disease. Neuroimmunomodulation 2018;25:201-5.
- 41. Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci 2014;8:65.
- 42. Ferragut Cardoso AP, Banerjee M, Nail AN, Lykoudi A, States JC. miRNA dysregulation is an emerging modulator of genomic instability. Semin Cancer Biol 2021;76:120-31.
- 43. Gareev I, Gileva Y, Dzidzaria A, Beylerli O, Pavlov V, Agaverdiev M, et al. Long non-coding RNAs in oncourology. Noncoding RNA Res 2021;6:139-45.
- 44. Alsayed RKME, Khan AQ, Ahmad F, Ansari AW, Alam MA, Buddenkotte J, et al. Epigenetic regulation of CXCR4 signaling in cancer pathogenesis and progression. Semin Cancer Biol 2022;86:697-708.
| APA | GURER E, SENTÜRK ÇIFTÇI H, Oguz R, KIVANC D, Kalayoglu Besisik S (2022). The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. , 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| Chicago | GURER EKIN ECE,SENTÜRK ÇIFTÇI HAYRIYE,Oguz Rustu,KIVANC DEMET,Kalayoglu Besisik Sevgi The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. (2022): 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| MLA | GURER EKIN ECE,SENTÜRK ÇIFTÇI HAYRIYE,Oguz Rustu,KIVANC DEMET,Kalayoglu Besisik Sevgi The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. , 2022, ss.419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| AMA | GURER E,SENTÜRK ÇIFTÇI H,Oguz R,KIVANC D,Kalayoglu Besisik S The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. . 2022; 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| Vancouver | GURER E,SENTÜRK ÇIFTÇI H,Oguz R,KIVANC D,Kalayoglu Besisik S The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. . 2022; 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| IEEE | GURER E,SENTÜRK ÇIFTÇI H,Oguz R,KIVANC D,Kalayoglu Besisik S "The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases." , ss.419 - 426, 2022. 10.4274/BMJ.galenos.2022.2022.2-6 |
| ISNAD | GURER, EKIN ECE vd. "The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases". (2022), 419-426. https://doi.org/10.4274/BMJ.galenos.2022.2022.2-6 |
| APA | GURER E, SENTÜRK ÇIFTÇI H, Oguz R, KIVANC D, Kalayoglu Besisik S (2022). The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. Bakırköy Tıp Dergisi, 18(4), 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| Chicago | GURER EKIN ECE,SENTÜRK ÇIFTÇI HAYRIYE,Oguz Rustu,KIVANC DEMET,Kalayoglu Besisik Sevgi The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. Bakırköy Tıp Dergisi 18, no.4 (2022): 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| MLA | GURER EKIN ECE,SENTÜRK ÇIFTÇI HAYRIYE,Oguz Rustu,KIVANC DEMET,Kalayoglu Besisik Sevgi The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. Bakırköy Tıp Dergisi, vol.18, no.4, 2022, ss.419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| AMA | GURER E,SENTÜRK ÇIFTÇI H,Oguz R,KIVANC D,Kalayoglu Besisik S The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. Bakırköy Tıp Dergisi. 2022; 18(4): 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| Vancouver | GURER E,SENTÜRK ÇIFTÇI H,Oguz R,KIVANC D,Kalayoglu Besisik S The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases. Bakırköy Tıp Dergisi. 2022; 18(4): 419 - 426. 10.4274/BMJ.galenos.2022.2022.2-6 |
| IEEE | GURER E,SENTÜRK ÇIFTÇI H,Oguz R,KIVANC D,Kalayoglu Besisik S "The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases." Bakırköy Tıp Dergisi, 18, ss.419 - 426, 2022. 10.4274/BMJ.galenos.2022.2022.2-6 |
| ISNAD | GURER, EKIN ECE vd. "The Role of the Chemokine CXCL12 on the Pathogenesis of Several Diseases". Bakırköy Tıp Dergisi 18/4 (2022), 419-426. https://doi.org/10.4274/BMJ.galenos.2022.2022.2-6 |
